Renovaro Inc. (NASDAQ:RENB) Sees Significant Growth in Short Interest

Renovaro Inc. (NASDAQ:RENB) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 5,060,000 shares, a growth of 30.7% from the December 15th total of 3,870,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 4.9 days. Approximately 6.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Renovaro

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new stake in shares of Renovaro during the 2nd quarter valued at approximately $79,000. SG Americas Securities LLC raised its holdings in shares of Renovaro by 193.3% during the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock worth $43,000 after purchasing an additional 34,090 shares during the period. Barclays PLC lifted its position in shares of Renovaro by 315.7% in the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after buying an additional 52,804 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Renovaro by 347.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after buying an additional 72,230 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Renovaro during the second quarter worth about $220,000. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Trading Down 5.7 %

NASDAQ:RENB traded down $0.04 during mid-day trading on Friday, hitting $0.71. The company had a trading volume of 624,909 shares, compared to its average volume of 1,725,119. The firm has a market capitalization of $112.22 million, a price-to-earnings ratio of -0.74 and a beta of 0.66. The business has a fifty day simple moving average of $0.99 and a 200-day simple moving average of $0.84. Renovaro has a 1 year low of $0.40 and a 1 year high of $5.25.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.